Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Ayala Pharmaceuticals Inc is a biotechnology business based in the US. Ayala Pharmaceuticals shares (AYLA) are listed on the NASDAQ and all prices are listed in US Dollars. Ayala Pharmaceuticals employs 34 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $6.74 |
|---|---|
| 52-week range | $6.26 - $28.68 |
| 50-day moving average | $9.27 |
| 200-day moving average | $10.58 |
| Wall St. target price | $22.38 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-2.87 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $6.74 from 2022-01-21
| 1 week (2022-01-14) | 1.66% |
|---|---|
| 1 month (2021-12-18) | N/A |
| 3 months (2021-10-22) | -30.73% |
| 6 months (2021-07-22) | -42.64% |
| 1 year (2021-01-22) | -48.75% |
|---|---|
| 2 years (2020-01-18) | N/A |
| 3 years (2019-01-18) | N/A |
| 5 years (2017-01-18) | N/A |
| Revenue TTM | $3.4 million |
|---|---|
| Gross profit TTM | $1 million |
| Return on assets TTM | -49.04% |
| Return on equity TTM | -91.76% |
| Profit margin | 0% |
| Book value | $2.91 |
| Market capitalisation | $92.4 million |
TTM: trailing 12 months
We're not expecting Ayala Pharmaceuticals to pay a dividend over the next 12 months.
Ayala Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.